Eighty-four of the sufferers who were randomly designated to the rituximab group and 81 of those who were randomly assigned to the control group completed six months of treatment without meeting criteria for early treatment failure, crossing over to the additional treatment group, switching to a therapy based on greatest medical judgment, or withdrawing from the process for other reasons . Efficacy Assessments End Points Sixty-three of the 99 sufferers in the rituximab group reached the principal end point, in comparison with 52 of 98 in the control group .It is anticipated that the counter claim in the Edinburgh Court of Session action will result in the restriction or revocation of Verathon’s patent. Aircraft has also lodged defences at the Courtroom of Session challenging Verathon to set out the basis because of its claim that Aircraft infringes the existing ‘131 patent. Despite having serious questions regarding its validity, Verathon’s ‘131 patent will not actually describe Aircraft’s products. At this point, in related activities raised by Aircraft, the European Patent Workplace has discovered Verathon’s ‘131 patent not valid as granted, and the U.S.